| Literature DB >> 25249821 |
Anna-Lena Cedströmer1, Margareta Ahlqwist2, Anna Andlin-Sobocki3, Lillemor Berntson4, Britt Hedenberg-Magnusson5, Lars Dahlström1.
Abstract
BACKGROUND: Juvenile idiopathic arthritis (JIA) is an autoimmune, heterogeneous disease and the temporomandibular joint (TMJ) can be affected, with consequences for mandibular growth and function. The aim of this study was to evaluate the importance of longitudinal medical treatment and the burden of disease activity on the development of temporomandibular condylar alterations as judged on panoramic radiographs.Entities:
Keywords: Adolescent; Arthritis juvenile rheumatoid/diagnoses; Child; Retrospective studies; Temporomandibular joint
Mesh:
Substances:
Year: 2014 PMID: 25249821 PMCID: PMC4171576 DOI: 10.1186/1546-0096-12-43
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Figure 1Panoramic radiograph on a patient with JIA with example of common alteration, flattening, on the left TMJ. Right side (H) is normal.
JIA patients examined with panoramic radiographs (n = 158), allocated to the eight ILAR categories
| Total | Systemic | Persistent oligo | Extended oligo | RF-negative polyarthritis | RF-positive polyarthritis | Psoriatic | ERA | Other arthritis | |
|---|---|---|---|---|---|---|---|---|---|
| Total n (% girls) | 158 (73) | 4 (50) | 62 (76) | 12 (67) | 43 (77) | 10 (100) | 17 (82) | 2 (0) | 8 (25) |
| Age at onset, median, 25/75th percentile yrs | 7.2 (3.4/10.8) | 4.8 (3.7/6.0) | 6.0 (2.1/9.3) | 4.4 (2.6/4.8) | 7.1 (3.8/9.8) | 11.7 (9.9/15.0) | 9.0 (4.0/13.1) | 13.5 (12.5/14.4) | 10.1 (9.3/13.0) |
| Disease duration, median, 25/75th percentile yrs | 2.5 (0.5/3.9) | 2.9 (0.9/4.9) | 2.6 (0.3/3.8) | 2.4 (0.6/4.4) | 3.0 (0.6/4.8) | 0.9 (0.1/1.5) | 2.6 (0.1/2.9) | 0.3 (0.1/0.5) | 1.7 (0.8/2.1) |
| Condylar alteration, n (%) | 68 (43) | 0 | 26 (42) | 9 (69) | 16 (37) | 7 (70) | 10 (56) | 0 | 3 (33) |
| Toadstool appearance, n (%) | 12 (8) | 0 | 4 (6) | 1 (8) | 4 (9) | 2 (20) | 0 | 1 | 0 |
Distribution of age at onset, disease duration, condylar alteration (shape or structural) and toadstool appearance is given.
A total of 158 patients with JIA examined with panoramic radiographs
| Total | Condylar alterations | No condylar alterations |
| |
|---|---|---|---|---|
| Total, n (% girls) | 158 (73) | 68 (78) | 90 (70) |
|
| Duration, yrs, median (25/75th percentile) | 2.5 (0.5/3.9) | 2.8 (0.6/4.7) | 2.3 (0.4/3.2) |
|
| “EU 1 any time”, n (%) | 15 (9) | 9 (13) | 6 (7) |
|
| Number of “active disease periods”, median (25/75th percentile) | 2.49 (1.0/3.0) | 2.87 (1.0/4.0) | 2.28 (1.0/3.0) |
|
| “Potent medication” any time, n (%) | 75 (47) | 41 (60) | 34 (38) |
|
| Number of “medication periods”, median (25/75th percentile) | 2.69 (1.0/4.0) | 3.06 (1.0/4.0) | 2.41 (1.0/3.0) |
|
| Both “MTX and TNF-alpha inhibitor” any time, n (%) | 43 (27) | 23 (34) | 20 (22) |
|
| “EU 1 or potent medication” any time, n (%) | 82 (52) | 43 (63) | 39 (43) |
|
| “EU 1 and potent medication” any time, n (%) | 15 (10) | 11 (16) | 4 (4) |
|
The association between condylar alterations, longitudinal disease activity and medication is presented. The bold values of column P is statistically significant (P =< 0.05).
Condylar alterations = shape or structural.
Duration = time from onset (yrs), as judged by the rheumatologist, to the panoramic examination.
“EU 1 any time” = active disease with increasing number of active joints any time for at least six months between onset and the panoramic examination.
Number of “active disease periods” = EU 1 and/or EU 2 (stable disease with unchanged number of active joints) for six months or more between onset and the panoramic examination.
“Potent medication” = MTX and/or TNF-alpha inhibitor and/or corticosteroid injections in the TMJ any time for at least six months between onset and the panoramic examination.
Number of “medication periods” = “potent medication” for six months or more between onset and the panoramic examination.
“MTX and TNF-alpha inhibitor any time” = intake of MTX and TNF-alpha any time for at least six months between onset and the panoramic examination.
“EU 1 and/or potent medication” any time = EU1 and/or potent medication for at least six months between onset and the panoramic examination.
Figure 2Results of bivariate logistic regression on the risk of condylar alterations on panoramic radiographs in patients with JIA (n = 158) presented in odds ratios (OR) (95% Cl) and P-values. The distribution of duration (time from onset to panoramic examination, yrs), “EU 1 any time” (active disease with increasing number of active joints any time for at least six months between onset and the panoramic examination), number of “active disease periods” (EU1 and/or EU2 (stable disease with unchanged number of active joints) for six months or more between onset and the panoramic examination), “potent medication” any time (MTX and/or TNF-alpha inhibitor and/or corticosteroid injections in the TMJ for at least six months between onset and the panoramic examination), number of “medication periods” (potent medication for six months or more between onset and the panoramic examination), “MTX + TNF-alpha inhibitor anytime” (intake of MTX and TNF-alpha any time for at least six months between onset and the panoramic examination). “EU 1 or potent medication” any time (EU 1 or potent medication for at least six months between onset and the panoramic examination) and “EU 1 and potent medication” any time (EU 1 and potent medication for at least six months between onset and the panoramic examination) are given.